1987PubMedRequires access

[Breast cancer and hormone therapy].

Masaru Izuo

Open publisher page 0 citations

Abstract

Recent changes in hormonal therapy for breast cancer were reviewed and discussed. In hormonal therapy for metastatic or recurrent cases, major forms of ablative therapy other than oophorectomy have been less popular because of the introduction of the hormone receptor assay, tamoxifen therapy, high-dose medroxyprogesterone acetate therapy, etc. Together with this, combined modality therapy including chemo-endocrine therapy or multi-hormone therapy has been investigated. Hormonal therapy as a post-surgical adjuvant therapy consists of oophorectomy (surgical or irradiation) and long-term administration of tamoxifen. Although these treatments are still associated with controversial results in several reports, further study and evaluation should be continued.

About this research paper

What this paper is about

Recent changes in hormonal therapy for breast cancer were reviewed and discussed. In hormonal therapy for metastatic or recurrent cases, major forms of ablative therapy other than oophorectomy have been less popular because of the introduction of the hormone receptor assay, tamoxifen therapy, high-dose medroxyprogesterone acetate therapy, etc. Together with this, combined modality therapy including chemo-endocrine therapy or multi-hormone therapy has been investigated. Hormonal therapy as a post-surgical adjuvant therapy consists of oophorectomy (surgical or irradiation) and long-term administration of tamoxifen. Although these treatments are still associated with controversial results in several reports, further study and evaluation should be continued.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Recent changes in hormonal therapy for breast cancer were reviewed and discussed. In hormonal therapy for metastatic or recurrent cases, major forms of ablative therapy other than oophorectomy have been less popular because of the introduction of the hormone receptor assay, tamoxifen therapy, high-dose medroxyprogesterone acetate therapy, etc. Together with this, combined modality therapy including chemo-endocrine therapy or multi-hormone therapy has been investigated. Hormonal therapy as a post-surgical adjuvant therapy consists of oophorectomy (surgical or irradiation) and long-term administration of tamoxifen. Although these treatments are still associated with controversial results in several reports, further study and evaluation should be continued.

Key concepts: Medicine, Hormonal therapy, Tamoxifen, Medroxyprogesterone acetate, Hormone therapy, Oophorectomy, Adjuvant therapy, Breast cancer

Related papers

Back to paper searchBrowse research topicsOriginal source
[Breast cancer and hormone therapy]. — Research Paper | ScholarLens